

**This Page Is Inserted by IFW Operations
and is not a part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problems Mailbox.**

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau





INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ :	A1	(11) International Publication Number:	WO 94/14808
C07D 471/04, A61K 31/435 // (C07D 471/04, 221:00, 209:00)		(43) International Publication Date:	7 July 1994 (07.07.94)
(21) International Application Number:	PCT/EP93/03536	(81) Designated States:	AU, BB, BG, BR, BY, CA, CZ, FI, HU, JP, KP, KR, KZ, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SK, UA, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).
(22) International Filing Date:	15 December 1993 (15.12.93)		
(30) Priority Data:	9226855.6 23 December 1992 (23.12.92) GB	Published	With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.
(71) Applicant:	FARMITALIA CARLO ERBA S.R.L. [IT/IT]; Via Carlo Imbonati, 24, I-20159 Milan (IT).		
(72) Inventors:	BUZZETTI, Franco; Via della Gallarana, 4, I-20052 Monza (IT). CRUGNOLA, Angelo; Via Ruggiero Settimo, 30, I-21100 Varese (IT). BALLINARI, DARIO; Via Jannozzi, 8, I-20097 San Donato Milanese (IT). GRECO, Felicita; Via IV novembre, 138, I-25010 Borgosatollo (IT).		
(74) Agent:	FARMITALIA CARLO ERBA S.R.L.; R.D/Patents & Documentation Department, Via Carlo Imbonati, 24, I-20159 Milan (IT).		

(54) Title: VINYLENE-AZAINDOLE DERIVATIVES AND PROCESS FOR THEIR PREPARATION

(57) Abstract

The present invention relates to the compounds of formula (I) wherein one of the groups X¹ to X⁴ is N and the others are CH; R is a group of formula (a), (b), (c), (d) or (e) in which n is zero or an integer of 1 to 5; R¹ is hydrogen, halogen, C₁-C₆ alkyl, C₁-C₆ alkoxy, nitro or a group -NR⁴R⁵ wherein each of R⁴ and R⁵ is independently hydrogen or C₁-C₆ alkyl; R² is hydrogen, C₁-C₆ alkyl or C₁-C₆ alkanoyl; R³ is hydrogen, halogen, hydroxy, C₁-C₆ alkoxy, carboxy, nitro or a group -NR⁴R⁵, wherein R⁴ and R⁵ are as defined above, and the pharmaceutically acceptable salts thereof. The compounds of formula (I) are useful as tyrosine kinase inhibitors.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				


- 1 -

VINYLENE-AZAINDOLE DERIVATIVES AND PROCESS FOR THEIR PREPARATION.

The present invention relates to new vinylene-azaindole derivatives, to a process for their preparation, to pharmaceutical compositions containing them and to their use as therapeutic agents.

The present invention provides compounds having the following general formula (I)


10



wherein

one of the groups X¹ to X⁴ is N and the others are CH;


R is a group of formula (a), (b), (c), (d) or (e)




(a)



(b)




(c)



(d)

- 2 -



(e)

in which

n is zero or an integer of 1 to 5;

R¹ is hydrogen, halogen, C₁-C₆ alkyl, C₁-C₆ alkoxy, nitro
5 or a group -NR⁴R⁵ wherein each of R₄ and R₅ is independently hydrogen or C₁-C₆ alkyl;

R² is hydrogen, C₁-C₆ alkyl or C₁-C₆ alkanoyl;

R₃ is hydrogen, halogen, hydroxy, C₁-C₆ alkoxy, carboxy, nitro or a group -NR⁴R⁵, wherein R⁴ and R⁵ are as defined above, and the pharmaceutically acceptable salts thereof.

In the compounds of the invention each of the substituents R and R¹ may be independently on either of the pyridine or pyrrole moieties of the bicyclic
15 azaindole ring.

The invention includes within its scope all the possible isomers, stereoisomers, in particular Z- and E-isomers and their mixtures, and the metabolites and the metabolic precursors or bio-precursors (otherwise known
20 as pro-drugs) of the compounds of formula (I).

The substituent R is preferably linked to position 2 or 3 of the azaindole ring, in particular to position 3.

- 3 -

The substituent R¹ is preferably on the pyridine moiety, in particular on the carbon adjacent to the nitrogen ring atom. When one of R¹ and R³ is nitro or a -NR⁴R⁵ group as defined above, then the other has preferably a different meaning. The R³ substituent is preferably in 5-position of the oxindole ring (e).

The alkyl groups and the alkyl moiety in the alkoxy and alkanoyl groups may be branched or straight alkyl chain.

A C₁-C₆ alkyl group is preferably a C₁-C₄ alkyl group, e.g. methyl, ethyl propyl, isopropyl, butyl, sec-butyl or tert-butyl, in particular methyl or ethyl.

A C₁-C₆ alkoxy group is preferably a C₁-C₃ alkoxy group, in particular methoxy, ethoxy or n-propoxy.

A C₂-C₆ alkanoyl group is preferably a C₂-C₃ alkanoyl group, in particular acetyl or propionyl.

A halogen is preferably fluorine, chlorine or bromine, in particular chlorine.

Pharmaceutically acceptable salts of the compounds of the invention include acid addition salts with inorganic, e.g. nitric, hydrochloric, hydrobromic, sulphuric, perchloric and phosphoric, acids, or organic, e.g. acetic, propionic, glycolic, lactic, oxalic, malonic, malic, maleic, tartaric, citric, benzoic, cinnamic, mandelic and salicylic, acids, and salts with inorganic, e.g. alkali metal, especially sodium or potassium, bases or alkaline-earth metal, especially calcium or magnesium, bases, or with organic bases, e.g.

- 4 -

alkylamines, preferably triethylamine.

As stated above, the present invention also includes within its scope pharmaceutically acceptable bio-precursors (otherwise known as pro-drugs) of the compounds of formula (I), i.e. compounds which have a different formula to formula (I) above but which nevertheless upon administration to a human being are converted directly or indirectly in vivo into a compound of formula (I).

10 Preferred compounds of the invention are the compounds of formula (I), wherein

the groups X^1 to X^4 are as defined above;

R is as defined above and is linked in position 2 or 3 of the azaindole ring;

15 n is zero;

R^1 is hydrogen or a halogen or C_1-C_3 alkoxy group linked to the carbon atom adjacent to the nitrogen atom in the pyridine moiety;

R^2 is hydrogen or C_1-C_3 alkyl; and, when R is group (e),

20 R^3 is hydrogen or a hydroxy group linked in position 5 of the oxoindole ring, and the pharmaceutically acceptable salts thereof.

More preferred compounds of the invention are the compounds of formula (I) in which

25 the groups X^1 to X^4 are as defined above;

R is as defined above and is linked in position 3 of the azaindole ring;

- 5 -

n is zero;


R¹ and R³ are hydrogen atoms; and, when R is group (e), R³ is hydrogen or a hydroxy group linked in position 5 of the oxindole ring and the pharmaceutically acceptable salts thereof.

Examples of specific compounds of the invention are the following compounds, which may be either Z- or E-diastereomers or Z,E-mixtures of said diastereomers:

- 2-cyano-3-(7-azaindol-3-yl)acrylamide;
10 2-cyano-3-(7-azaindol-3-yl)acrylanilide;
2-cyano-3-(7-azaindol-3-yl)thioacrylamide;
2-cyano-3-(7-azaindol-3-yl)acrylonitrile;
3-[(7-azaindol-3-yl)methylen]-2-oxindole;
5-hydroxy-3-[(7-azaindol-3-yl)methylen]-2-oxindole;
15 2-cyano-3-(6-azaindol-3-yl)acrylamide;
2-cyano-3-(6-azaindol-3-yl)acrylanilide;
2-cyano-3-(6-azaindol-3-yl)thioacrylamide;
2-cyano-3-(6-azaindol-3-yl)acrylonitrile;
3-[(6-azaindol-3-yl)methylen]-2-oxindole;
20 5-hydroxy-[(6-azaindol-3-yl)methylen]-2-oxindole;
2-cyano-3-(5-azaindol-3-yl)acrylamide;
2-cyano-3-(5-azaindol-3-yl)acrylanilide;
2-cyano-3-(5-azaindol-3-yl)thioacrylamide;
2-cyano-3-(5-azaindol-3-yl)acrylonitrile;
25 3-[(5-azaindol-3-yl)methylen]-2-oxindole;


- 6 -

- 5-hydroxy-3-[5-azaindol-3-yl]-2-oxindole;
 2-cyano-3-(4-azaindol-3-yl)acrylamide;
 2-cyano-3-(4-azaindol-3-yl)acrylanilide;
 2-cyano-3-(4-azaindol-3-yl)thioacrylamide;
 5 2-cyano-3-(4-azaindol-3-yl)acrylonitrile;
 3-[(4-azaindol-3-yl)methylen]-2-oxindole;
 5-hydroxy-3-[(4-azaindol-3-yl)methylen]-2-oxindole;
 and, if the case, the pharmaceutically acceptable salts
 thereof.
- 10 The compounds of the invention, and the pharmaceutically
 acceptable salts thereof, can be obtained by a process
 comprising the condensation of an aldehyde of formula
 (II)




- 15 wherein the groups X¹ to X⁴, R¹ and R² are as defined
 above, with a compound of formula (a'), (b'), (c'), (d')
 or (e'), respectively:


- 7 -



(a')




(b')



(c')



(d')



(e)

wherein R^3 and n are as defined above, and, if desired, converting a compound of formula (I) into another 5 compound of formula (I), and/or, if desired, converting a compound of formula (I) into a pharmaceutically acceptable salt thereof, and/or, if desired, converting a salt into a free compound, and/or, if desired, separating a mixture of isomers of a compound of formula 10 (I) into the single isomers.

Each of the substituents R^1 and -CHO in a compound of formula (II) may be independently on either of the pyridine or pyrrole moiety of the azaindole ring.

The reaction of a compound of formula (II) with a 15 compound of formula (a'), (b'), (c'), (d') or (e') may be carried out according to known methods, as herebelow described; preferably in the presence of a basic catalyst, e.g. pyridine, piperidine, dimethylamine, or a suitable alkali metal hydroxide or alkoxide.

- 8 -

For example the reaction of a compound of formula (II) with a compound of formula (a'), (b'), (c'), (d') or (e'), respectively, may be carried out under the conditions of the Knoevenagel reactions as described e.g. by Jones in Organic Reactions 15, 204 (1967). Suitable catalysts are organic bases such as pyridine, piperidine or diethylamine.

The condensation may be performed in an inert organic solvent e.g. pyridine, ethanol, methanol, benzene or dioxane at temperatures ranging from about 0°C to about 100°C.

Preferably the reaction is carried out in warm ethanol solution in the presence of piperidine catalyst.

A compound of formula (I) can be converted into another compound of formula (I) according to known methods. For example the de-etherification of a compound of formula (I), wherein R¹ and/or R³ is methoxy, so as to obtain a compound of formula (I), wherein R¹ and/or R³ is hydroxy, can be carried out for example with boron tribromide as described by J.F.N. McOmie in Tetrahedron 24, 2289 (1968). The reaction may be performed in an inert organic solvent such as dichloromethane, pentane or benzene under an inert, e.g. nitrogen, atmosphere at temperatures ranging from about -78°C to about room temperature.

The conversion of a compound of formula (I) in which R³ is nitro into the corresponding compound of formula (I)

- 9 -

wherein R³ is amino may be carried out following known methods, for example with a variety of reducing agents, e.g. sodium sulfide in hydroalcoholic solution, metallic iron with ammonium chloride in aqueous solvent, or, for 5 instance, catalytic hydrogenations using, e.g., palladium charcoal catalyst at low hydrogen pressure in an inert organic solvent.

The alkylation of a compound of formula (I), wherein R² is hydrogen, so as to obtain the corresponding compound 10 of formula (I) wherein R² is a C₁-C₆ alkyl group, may be obtained, e.g., by reaction with sodium hydride and C₁-C₆ alkyl iodide in a high boiling aromatic solvent such as xylene.

The acylation of a compound of formula (I), wherein R² is 15 hydrogen, in order to obtain the corresponding compound of formula (I) wherein R² is a C₂-C₆ alkanoyl, can be performed, e.g., by reaction with a suitable carboxylic anhydride in the presence of a basic agent at temperatures ranging from room temperature to reflux 20 temperatures.


The alkoxylation of a compound of formula (I) wherein R¹ is a halogen adjacent to the pyridine nitrogen, so as to obtain the corresponding compound of formula (I) wherein 25 R¹ is C₁-C₆ alkoxy, may be carried out, e.g., by reaction with a sodium alkoxide in refluxing DMF solution.

The amination of a compound of formula (I) wherein R¹ is a halogen adjacent to the pyridine nitrogen, so as to

- 10 -

obtain the corresponding compound of formula (I) wherein R¹ is a -NR⁴R⁵ group in which one or both of R⁴ and R⁵ is C₁-C₆ alkyl, may be carried out, e.g., by reaction with the corresponding amine of formula NHR³R⁴ at reflux 5 temperature.

The optional salification of a compound of formula (I) as well as the conversion of a salt into the free compound and the separation of a mixture of isomers into the single isomers may be carried out by conventional 10 methods. For example the separation of a mixture of geometric isomers, e.g. cis- and trans-isomers, may be carried out by fractional crystallization from a suitable solvent or by chromatography, either column chromatography or high pressure liquid chromatography. 15 The compounds of formula (II) may be obtained according to known methods from compounds of formula (III).




wherein the groups X¹ to X⁴, R¹ and R² are as defined above.

20 For example the 3-formylazaindole derivative of formula (II) can be obtained from a compound of formula (III) by formylation with N-methyl-formanilide or DMF and phosphorous oxychloride according to the well known

- 11 -

Vilsmeye-Haack method (for a review see W.G. Jackson et al., J. Am. Chem. Soc. 103, 533, 1981). The 2-formylazaindole derivatives are obtained when the 3-position is occupied.

- 5 The compounds of formula (III) are known or may be obtained by known methods from known compounds. For example according to R.R. Lorenz et al. (J. Org. Chem. 30, 2531, 1965) the various parent azaindoles (IIIA) may be obtained following the 3-step process herebelow depicted, starting from the appropriate aminomethyl-pyridine (IV) via the formimidates (V) and the formamidines (VI).
- 10



Thus 7-azaindole (IIIA, X⁴=N, X¹=X²=X³=CH) is obtained
 15 from 2-amino-3-methylpyridine (IV, X⁴=N, X¹=X²=X³=CH) whilst 4-amino-3-methylpyridine (IV, X²=N, X¹=X³=X⁴=CH) gives rise to 5-azaindole (IIIA, X²=N, X¹=X³=X⁴=CH).

- 12 -

The 4-azaindole (IIIA, $X^1=N$, $X^2=X^3=X^4=CH$) is obtained from 3-amino-2-methylpyridine (IV, $X^1=N$, $X^2=X^3=X^4=CH$).

The compounds of formula (a'), (b'), (c'), (d') and (e') are known or may be obtained by known methods from known 5 compounds.

When in the new compounds of the present invention and in the intermediate products used for their preparation groups are present, which need to be protected before submitting them to the hereabove illustrated reactions, 10 they may be protected before the reaction takes place and then deprotected at the end of the reaction, according to well known methods in organic chemistry.

Pharmacology

The compounds of the invention possess specific tyrosine 15 kinase inhibiting activity. It is believed that tyrosine kinase inhibitors may be of great importance in the control of uncontrolled cellular reproduction, i.e., in cellular reproduction disorders. Hence the compounds according to the present invention can be useful in the 20 treatment of pathological proliferation disorders in mammals, including humans. Typical examples of such disorders are tumors, including leukemia, and psoriasis. They can also be useful in inhibiting the development of the atheromatous plaque. Furthermore, the compounds of 25 the invention have been found to be active as angio-

- 13 -

genesis inhibitors.

An angiogenesis inhibitor is an agent capable of suppressing the growth of new blood vessels. Therefore, the compounds of the present invention are useful in 5 treating several pathological conditions in mammals, including humans, where the growth of new blood vessels is detrimental, for example in chronic inflammation, diabetic retinopathy, psoriasis, rheumatoid arthritis, tumor growth, in particular solid tumors and development 10 of metastases.

Besides, the compounds of the invention possess immuno-modulating activity and in particular can be used in mammals, including humans, as immunosuppressive agents for the prevention and treatment of rejection phenomena 15 associated with tissue and organ transplantations, graft-versus-host diseases and autoimmune diseases.

Recent studies on the molecular basis of neoplastic transformation have identified a family of genes, designed oncogenes, whose aberrant expression causes 20 tumorigenesis.

For example, the RNA tumor viruses possess such an oncogene sequence whose expression determines neoplastic conversion of infected cells. Several of their oncogene-encoded proteins, such as pp60^{src}, p70^{raf-1}, p130^{gap-fps} and 25 p70^{gap-fgr} display protein tyrosine kinase activity, that is they catalyse the transfer of the γ -phosphate from adenosine triphosphate (ATP) to tyrosine residues in

- 14 -

protein substrate. In normal cells, several growth factor receptors, for example the receptors for PDGF, EGF, α -TGF and insulin, display tyrosine kinase activity.

- 5 Binding of the growth factor (GF) activates the receptor tyrosine kinase to undergo autophosphorylation and to phosphorylate closely adjacent molecules on tyrosine. Therefore, it is thought that the phosphorylation of these tyrosine kinase receptors plays an important role
- 10 in signal transduction and that the principal function of tyrosine kinase activity in normal cells is to regulate cell growth. Perturbation of this activity by oncogenic tyrosine kinases that are either overproduced and/or display altered substrate specificity may cause
- 15 loss of growth control and/or neoplastic transformation. Accordingly, a specific inhibitor of tyrosine kinase can be useful in investigating the mechanism of carcinogenesis, cell proliferation and differentiations and it can be effective in prevention and chemotherapy of
- 20 cancer and in other pathological proliferative conditions, for instance as mentioned above.
- The tyrosine specific protein kinase activity of these compounds is shown, e.g., by the fact that they are active in the in vitro test described herebelow.

- 25 Tyrosine kinase purification. The enzyme used in our test was the p45 v-abl tyrosine kinase which represents

- 15 -

the catalytic domain of the Abelson tyrosine kinase (isolated from the Abelson murine leukemia virus). The p45 v-abl kinase was produced and isolated as described by Wang et al. in J. Biol. Chem. 260, 64 (1985) and by 5 Ferguson et al. in J. Biol. Chem. 260, 3652 (1985) and in Biochem. J. 257, 321 (1989).

Exogenous Substrate Kinase Assay. (Val^5)-Angiotensin II phosphorylation was performed by incubation with 40 ng of purified abl-kinase and (γ - ^{32}P)-ATP, in 50 μl of buffer containing Tris-HCl 25 mM, pH 8.0, MgCl_2 , 10 mM and dithiothreitol 0.1 mM (kinase buffer). The reaction mixture was incubated for the indicated time at 30°C and the reaction stopped by adding 50 μl of 5% trichloroacetic acid.

After a brief incubation on ice, tubes were centrifuged. The supernatants were spotted on phosphocellulose paper squares (Whatman P-81) and washed extensively in acetic acid. The radioactivity bound to dried phosphocellulose squares was measured in a liquid scintillation counter.

IC_{50} values were calculated from triplicate determinations of each experimental point. Each inhibitor was tested at concentrations ranging from 0 to 400 μg in the presence of fixed concentrations of peptide (2 mM) and ATP (50 μM).

The activity data of two representative compounds of the present invention are set out in Table 1.

- 16 -

Table 1

p45 v-abl kinase inhibition	IC ₅₀ (μM)
3-[(7-azaindol-3-yl)methylen]-2-oxindole	0.05
2-cyano-3-(7-azaindol-3-yl)acrylamide	4.7

- 5 In view of their high activity and low toxicity, the compounds of the invention can be used safely in medicine. For example, the approximate acute toxicity (LD₅₀) of the compounds of the invention in the mouse, determined by single administration of increasing doses
10 and measured on the seventh day after the treatment, was found to be negligible.
- The compounds of the invention can be administered in a variety of dosage forms, e.g. orally, in the form of tablets, capsules, sugar- or film-coated tablets, liquid
15 solutions or suspensions; rectally, in the form of suppositories; parenterally, e.g. intramuscularly, or by intravenous injection or infusion; or topically.
- The dosage depends on the age, weight, condition of the patient and administration route; for example, the
20 dosage adopted for oral administration to adult humans may range from about 10 to about 150-200 mg per dose, from 1 to 5 times daily. Of course, these dosage regimens may be adjusted to provide the optimal therapeutic response.
- 25 The invention includes pharmaceutical compositions

- 17 -

comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof in association with a pharmaceutically acceptable excipient (which can be a carrier or diluent).

5 The pharmaceutical compositions containing the compounds of the invention are usually prepared following conventional methods and are administered in a pharmaceutically suitable form.

For example, the solid oral forms may contain, together
10 with the active compound, diluents, e.g., lactose, dextrose, saccharose, cellulose, corn starch or potato starch; lubricants, e.g. silica, talc, stearic acid, magnesium or calcium stearate, and/or polyethylene glycols; binding agents, e.g. starches, arabic gums,
15 gelatin, methylcellulose, carboxymethylcellulose or polyvinyl pyrrolidone; disaggregating agents, e.g. a starch, alginic acid, alginates or sodium starch glycolate, effervesing mixtures; dyestuffs; sweeteners; wetting agents, such as lecithin, polysorbates, lauryl-sulphates; and, in general, non-toxic and pharmaco-
20 logically inactive substances used in pharmaceutical formulations. Said pharmaceutical preparations may be manufactured in known manner, for example, by means of mixing, granulating, tabletting, sugar-coating or film-coating processes.

The liquid dispersion for oral administration may be e.g., syrups, emulsions and suspensions.

- 18 -

The syrup may contain as carrier, for example, saccharose or saccharose with glycerine and/or mannitol and/or sorbitol.

The suspensions and the emulsions may contain as 5 carrier, for example, a natural gum, agar, sodium alginate, pectin, methylcellulose, carboxymethyl-cellulose or polyvinyl alcohol.

The suspensions or solutions for intramuscular injections may contain, together with the active 10 compound, a pharmaceutically acceptable carrier, e.g., sterile water, olive oil, ethyl oleate, glycols, e.g., propylene glycol, and, if desired, a suitable amount of lidocaine hydrochloride.

The solutions for intravenous injections or infusion may 15 contain as carrier, for example, sterile water or, preferably, they may be in the form of sterile, aqueous, isotonic saline solutions.

The suppositories may contain, together with the active compound, a pharmaceutically acceptable carrier, e.g., 20 cocoa-butter, polyethylene glycol, a polyoxyethylene sorbitan fatty acid ester surfactant or lecithin.

Compositions for topical application, e.g., creams, lotions, or pastes, can be prepared by admixing the active ingredient with a conventional oleaginous or 25 emulsifying excipient.

A further object of the present invention is a combined method of treatment of cancer in mammals, including

- 19 -

humans, in need of such treatment, said method comprising administering

- 1) a compound of formula (I), or a pharmaceutically acceptable salt thereof, and
- 5 2) an additional antitumor agent, in amounts, and close enough together in time sufficient to produce a therapeutically useful effect.

Object of the present invention is also to provide products containing a compound of formula (I), or a 10 pharmaceutically acceptable salt, and an additional antitumor agent as a combined preparation for simultaneous, separate or sequential use in anti-cancer therapy.

The term "antitumor agent" is meant to comprise both a 15 single antitumor drug and "cocktails", i.e. a mixture of such drugs, according to the clinical practice.

Antitumor agents that can be formulated with a compound of the invention or, alternatively, can be administered in a combined method of treatment, are, e.g., 20 doxorubicin, daunomycin, epirubicin, idarubicin, etoposide, fluorouracil, mephalan, cyclophosphamide, bleomycin, vinblastin and mitomycin or a mixture of two or more thereof.

The compounds of the invention can therefore be used in 25 a treatment to ameliorate a cancer pathology. They may be administered to a patient suffering from a cancer treatable with an antitumor agent, for example an

- 20 -

anthracycline glycoside such as doxorubicin, daunomycin, epirubicin or idarubicin as mentioned above, together with the antitumor agent.

A compound of the invention and an antitumor agent such 5 as, e.g., an anthracycline glycoside can be administered to improve the condition of a patient having, e.g., a leukaemia such as myeloblastic leukaemia, lymphoma, sarcoma, neuroblastoma, Wilm's tumor or malignant neoplasm of the bladder, breast, lung or thyroid.

10 The following examples illustrate but do not limit the invention:

Example 1

(Z)-3-[(7-azaindol-3-yl)methylen]-2-oxindole

(I, $X^1=N$, $X^1=X^2=X^3=CH$, $R^1=R^2=R^3=H$)

15 A solution of 3-formyl-7-azaindole (1.46 g, 0.010 mol) 2-oxindole (1.332 g, 0.010 mol) and piperidine (0.255 g, 0.003 mol) in absolute ethanol (50 ml) is heated for 3 h at reflux. The reaction mixture is chilled to room temperature, the precipitate filtered, the residue 20 washed with ice-cooled ethanol and dried under vacuum. Almost pure title compound is so obtained in 81% yield (2.126 g).

Compounds of higher purity are obtained by crystallization from ethanol. m.p. >280°C.

- 21 -

C₁₆H₁₁N₃O requires : C 73.55 H 4.24 N 16.08

found : C 73.33 H 4.29 N 16.05

MS m/z : 261.

NMR δ ppm (DMSO): 6.84 (1H,d,J=7.6 Hz), 6.99 (1H,t,J=7.6 Hz), 7.15 (1H,t,J=7.6 Hz), 7.27 (1H,dd,J=4.7, 8.0 Hz), 7.87 (1H,d,J=7.6 Hz), 8.13 (1H,S), 8.33 (1H,dd,J=1.5, 4.7 Hz), 8.60 (1H,dd,J=1.5, 8.0 Hz), 9.50 (1H,S), 10.57 (1H,bs), 12.5 (1H,bs).

According to the above described procedure and starting
from the appropriate compounds of formula (II) and of
formulae (a'), (b'), (c'), (d') and (e'), respectively
one can prepare the following compounds as single E- or
Z-isomers, as well as their E,Z-mixtures:

2-cyano-3-(7-azaindol-3-yl)acrylamide.

MS m/z : 212.

NMR δ ppm (DMSO): 7.30 (1H,dd,J=4.9, 7.8 Hz), 7.55, 7.80
(two bs, 2H), 8.35-8.50 (4H,m), 12.9 (1H,bs);

2-cyano-3-(7-azaindol-3-yl)acrylanilide;

2-cyano-3-(7-azaindol-3-yl)thioacrylamide;

20 2-cyano-3-(7-azaindol-3-yl)acrylonitrile;

5-hydroxy-3-[(7-azaindol-3-yl)methylen]-2-oxindole;

2-cyano-3-(6-azaindol-3-yl)acrylamide;

2-cyano-3-(6-azaindol-3-yl)acrylanilide;

2-cyano-3-(6-azaindol-3-yl)thioacrylamide;

25 2-cyano-3-(6-azaindol-3-yl)acrylonitrile;

3-[(6-azaindol-3-yl)methylen]-2-oxindole;

- 22 -

- 5-hydroxy-[(6-azaindol-3-yl)methylen]-2-oxindole;
2-cyano-3-(5-azaindol-3-yl)acrylamide;
2-cyano-3-(5-azaindol-3-yl)acrylanilide;
2-cyano-3-(5-azaindol-3-yl)thioacrylamide;
5 2-cyano-3-(5-azaindol-3-yl)acrylonitrile;
3-[(5-azaindol-3-yl)methylen]-2-oxindole;
5-hydroxy-3-[5-azaindol-3-yl]-2-oxindole;
2-cyano-3-(4-azaindol-3-yl)acrylamide;
2-cyano-3-(4-azaindol-3-yl)acrylanilide;
10 2-cyano-3-(4-azaindol-3-yl)thioacrylamide;
2-cyano-3-(4-azaindol-3-yl)acrylonitrile;
3-[(4-azaindol-3-yl)methylen]-2-oxindole; and
5-hydroxy-3-[(4-azaindol-3-yl)methylen]-2-oxindole.

Example 2

- 15 5-Hydroxy-3-[(7-azaindol-3-yl)methylen]-2-oxindole
(I, X¹=N, X¹=X²=X³=CH, R=e, R¹=R²=H, R³=5-OH).

To a stirred solution of 5-methoxy-3-[(7-azaindol-3-yl)methylen]-2-oxindole (2.91 g, 0.010 mol) in anhydrous dichloromethane (100 ml) is added at -78°C under nitrogen, over a period of 20 min, a 1M solution of boron tribromide in dichloromethane (30 ml, 0.030 mol). The resulting mixture is stirred for another 1 h at -78°C and then allowed to warm up to r.t. After stirring

- 23 -

for 1.5 h at r.t. the mixture is cooled to -10°C and then quenched by dropwise addition of water (100 ml) over a 10-min period. After addition of ethyl acetate (100 ml) the organic layer is separated, washed with 5 water, dried over Na₂SO₄ and evaporated under vacuum to dryness. The residue is crystallized from ethanol thus giving pure title compound in 70% yield (1.94 g).

C₁₆H₁₁N₃O₂ requires : C 69.31 H 4.00 N 15.15
found : C 69.15 H 4.10 N 15.05

10 MS m/z : 277.

Following the above described procedure and starting from a phenolic methyl ether of formula (I), which, e.g., may be obtained according to the procedure described in example 1, the corresponding phenolic 15 compound of formula (I) may be obtained.

Example 3

5-Amino-3-[(7-azaindol-3-yl)methylen]-2-oxindole
(I, X⁴=N, X¹=X²=X³=CH, R=e, R¹=R²=H, R³=5-NH₂)

To a solution of 5-nitro-3-[(7-azaindol-3-yl)methylen]-20 2-oxindole (3.06 g, 0.010 mol) in anhydrous ethanol (200 ml) is added palladium on charcoal (100 mg) and the mixture is hydrogenated at r.t. and atmospheric pressure until 3 equivalent of hydrogen has been taken up. The

- 24 -

hydrogen uptake is graphed as a function of time. The catalyst is filtered and the solution concentrated under vacuum until crystallization begins. Then the mixture is cooled to 0-5°C, filtered, the residue washed with ice-cooled ethanol and dried under vacuum.

5 Thus almost pure title compound is obtained in 80% yield (2.21 g).

$C_{16}H_{12}N_4O$ requires : C 69.55 H 4.38 N 20.28
found : C 69.47 H 4.25 N 20.30

10 MS m/z : 276.

Proceeding analogously and starting from a nitro compound of formula (I), which, e.g., may be obtained according to the procedure described in Example 1, the corresponding amino compound of formula (I) can be 15 obtained.

Example 4

(Z)-3-[(1-methyl-7-azaindol-3-yl)methylen]-2-oxindole
(I, $X^4=N$, $X^1=X^2=X^3=CH$, $R=e$, $R^1=R^3=H$, $R^2=CH_3$)

To a suspension of 95% sodium hydride (0.280 g, 0.011 mol) in DMF (100 ml) cooled with an ice-n-propanol bath 20 is added over 15 min with stirring a solution of (Z)-3-[(7-azaindol-3-yl)methylen]-2-oxindole (2.61 g, 0.010 mol) in DMF (50 ml). When the evolution of hydrogen stopped, a solution of iodomethane (1.56 g, 0.011 mol)

- 25 -

in DMF (50 ml) is added over 15 min and the mixture is stirred at r.t. for 3 h. Most of the DMF is distilled off in vacuo, water is then added to the residue and the product extracted into ethyl acetate. The organic solution containing the desired product is dried (Na₂SO₄), the solvent evaporated and the remaining oil is crystallized by trituration with ethanol. Thus pure title compound is obtained in 60% yield.

C₁₇H₁₃N₃O requires : C 74.19 H 4.73 N 15.27
10 found : C 74.05 H 4.55 N 15.05
MS m/z : 275.

By this procedure compounds of formula (I) in which R² is C₁-C₆ alkyl can be prepared from compounds of formula (I) in which R² is hydrogen.

15 Example 5

(Z)-3-[(1-acetyl-7-azaindol-3-yl)methylen]-2-oxindole
(I, X⁴=N, X¹=X²=X³=CH, R=e, R¹=R³=H, R²=COCH₃).

A mixture of (Z)-3-[(7-azaindol-3-yl)methylen]-2-oxindole (2.61 g, 0.010 mol), potassium acetate (0.98 g, 0.010 mol) and acetic anhydride (10 ml) is heated at reflux temperature for 15 h and then concentrated under vacuum. The residue is taken up with ethyl acetate and water, the organic phase separated, washed with water, dried over Na₂SO₄ and evaporated under vacuum. The

- 26 -

residue is crystallized from ethanol to give pure title compound in 65% yield.

C₁₈H₁₃N₁O₂ requires : C 71.28 H 4.32 N 13.85

found : C 71.15 H 4.25 N 13.65

5 MS m/z : 303

By this procedure compounds of formula (I) in which R² is acetyl can be prepared from compounds of formula (I) wherein R² is hydrogen.

Example 6

10 3-[(4-dimethylamino-1-methyl-5-azaindol-3-yl)methylen]-2-oxindole.

(I, X²=N, X¹=X³=X⁴=CH, R=e, R¹=4-NMe₂, R²=Me, R³=H)

A mixture of 3-[(4-chloro-1-methyl-5-azaindol-3-yl)methylen]-2-oxindole (3.095 g, 0.010 mol) and 15 dimethylamine (4.51 g, 0.1 mol) is heated at about 150°C for 20 h in a pressure vessel. The excess of dimethylamine is evaporated under vacuum, the residue taken up in ethyl acetate after alkalization with sodium hydroxyde solution, the organic layer separated, washed 20 with water, dried and evaporated under vacuum. The residue is chromatographed on a silica gel column using dichloromethane-ethanol mixtures as eluant, thus giving pure title compound.

- 27 -

C₁₉H₁₈N₄O requires : C 71.68 H 5.70 N 17.60

found : C 71.51 H 5.65 N 17.55

MS m/z : 318.

By proceeding analogously compounds of formula (I) 5 wherein R¹ is a -NR⁴R⁵ group can be obtained from compounds of formula (I) wherein R¹ is chlorine.

Example 7

3-[(4-methoxy-1-methyl-5-azaindol-3-yl)methylen]-2-oxindole.

10 (I, X²=N, X¹=X³=X⁴=CH, R=e, R¹=OMe, R²=Me, R³=H)

A solution of 3-[(4-chloro-1-methyl-5-azaindol-3-yl)methylen]-2-oxindole (3.095 g, 0.010 mol) and potassium methoxide (0.70 g, 0.010 mol) in methanol (50 ml) is heated in a sealed tube for 6 h at about 120°C. The 15 solution is concentrated under vacuum, diluted with water and the product extracted with ethyl acetate. The organic layer is washed, dried and evaporated under vacuum. The residue is submitted to column chromatography on silica gel using dichloromethane-methanol mixtures as eluant. Thus pure title compound is obtained 20 in about 50% yield.

C₁₈H₁₅N₃O₂ requires : C 70.81 H 4.95 N 13.76

found : C 70.75 H 4.90 N 13.72

- 28 -

MS m/z : 305.

According to this procedure and starting from a compound of formula (I) wherein R¹ is chlorine and using the appropriate potassium C₁-C₆ alkoxide one can obtain a 5 compound of formula (I) wherein R¹ is C₁-C₆ alkoxy.

Example 8

7-Azaindole-3-carboxaldehyde.

(II, X⁴=N, X¹=X²=X³=CH, R¹=R²=H)

A solution of 7-azaindole (23.6 g, 0.20 mol) and 10 hexamethylenetetramine (42 g, 0.30 mol) in 33% acetic acid (84 g, 1.4 mol and 168 ml H₂O) is refluxed for 6 h. The resulting clear yellow solution is diluted with water, and the product is allowed to crystallize in the refrigerator overnight. Recrystallization of the crude 15 product from water gave almost pure title compound in 50% yield (14.9 g).

m.p. 216-218°C

C₈H₆N₂O requires : C 65.74 H 4.13 N 19.17

found : C 65.65 H 4.05 N 19.05

20 MS m/z : 146.

The isomeric 4-, 5- or 6-azaindole-3-carboxaldehydes can be obtained by the above described procedure starting from the 4-, 5- or 6-azaindoles respectively.

- 29 -

Example 9

Tablets each weighing 0.150 g and containing 25 mg of the active substance, can be manufactured as follows:
composition (for 10,000 tablets):

5	3-[(7-azaindol-3-yl)methylen]-2-oxindole	
	Lactose	250 g
	Corn starch	800 g
	Talc powder	415 g
10	Magnesium stearate	30 g
		5 g

The 3-[(7-azaindol-3-yl)methylen]-2-oxindole, the lactose and half the corn starch are mixed; the mixture is then forced through a sieve of 0.5 mm mesh size. Corn starch (10 g) is suspended in warm water (90 ml) and the resulting paste is used to granulate the powder. The granulate is dried, comminuted on a sieve of 1.4 mm mesh size, then the remaining quantity of starch, talc and magnesium stearate is added, carefully mixed and processed into tablets.

- 30 -

Example 10

Capsules, each dosed at 0.200 g and containing 20 mg of the active substance can be prepared.

Composition for 500 capsules:


5	2-cyano-3-(7-azaindol-3-yl)acrylamide	10 g
	Lactose	80 g
	Corn starch	5 g
	Magnesium stearate	5 g

This formulation is encapsulated in two-piece hard
10 gelatin capsules and dosed at 0.200 g for each capsule.

- 31 -


CLAIMS

1. A compound of general formula (I)



wherein

5 one of the groups X¹ to X⁴ is N and the others are CH;
R is a group of formula (a), (b), (c), (d) or (e)



(a)




(b)



(c)



(d)



(e)

- 32 -

in which

n is zero or an integer of 1 to 5;

R¹ is hydrogen, halogen, C₁-C₆ alkyl, C₁-C₆ alkoxy, nitro or a group -NR⁴R⁵, wherein each of R⁴ and R⁵

5 is independently hydrogen or C₁-C₆ alkyl;

R² is hydrogen, C₁-C₆ alkyl, or C₂-C₆ alkanoyl;

R³ is hydrogen, halogen, hydroxy, C₁-C₆ alkoxy, carboxy, nitro or a group -NR⁴R⁵, wherein R⁴ and R⁵ are as defined above, and the pharmaceutically acceptable salts thereof.

10

2. A compound of formula (I), according to claim 1, wherein:

the groups X¹ to X⁴ are as defined in claim 1;

15 R is as defined in claim 1 and it is linked in position 2 or 3 of the azaindole ring;

n is zero;

R¹ is hydrogen, or a halogen or C₁-C₃ alkoxy group linked to the carbon atom adjacent to the nitrogen atom in the pyridine moiety;

R² is hydrogen or C₁-C₄ alkyl; and, when R is group (e),

R³ is hydrogen or a hydroxy group linked in position 5 of the oxindole ring, and the pharmaceutically acceptable salts thereof.

25

- 33 -


3. A compound selected from a group consisting of the following compounds, which, when appropriate, may be either Z- or E-diastereomers or Z,E-mixtures of said diastereomers:

- 5 2-cyano-3-(7-azaindol-3-yl)acrylamide;
 2-cyano-3-(7-azaindol-3-yl)acrylanilide;
 2-cyano-3-(7-azaindol-3-yl)thioacrylamide;
 2-cyano-3-(7-azaindol-3-yl)acrylonitrile;
 3-[(7-azaindol-3-yl)methylen]-2-oxindole;
- 10 5-hydroxy-3-[(7-azaindol-3-yl)methylen]-2-oxindole;
 2-cyano-3-(6-azaindol-3-yl)acrylamide;
 2-cyano-3-(6-azaindol-3-yl)acrylanilide;
 2-cyano-3-(6-azaindol-3-yl)thioacrylamide;
 2-cyano-3-(6-azaindol-3-yl)acrylonitrile;
- 15 3-[(6-azaindol-3-yl)methylen]-2-oxindole;
 5-hydroxy-[(6-azaindol-3-yl)methylen]-2-oxindole;
 2-cyano-3-(5-azaindol-3-yl)acrylamide;
 2-cyano-3-(5-azaindol-3-yl)acrylanilide;
 2-cyano-3-(5-azaindol-3-yl)thioacrylamide;
- 20 2-cyano-3-(5-azaindol-3-yl)acrylonitrile;
 3-[(5-azaindol-3-yl)methylen]-2-oxindole;
 5-hydroxy-3-[5-azaindol-3-yl]-2-oxindole;
 2-cyano-3-(4-azaindol-3-yl)acrylamide;
 2-cyano-3-(4-azaindol-3-yl)acrylanilide;
- 25 2-cyano-3-(4-azaindol-3-yl)thioacrylamide;
 2-cyano-3-(4-azaindol-3-yl)acrylonitrile;





- 34 -

3-[(4-azaindol-3-yl)methylen]-2-oxindole;
 5-hydroxy-3-[(4-azaindol-3-yl)methylen]-2-oxindole;
 and, if the case, the pharmaceutically acceptable salts thereof.


5 4. A process for the preparation of a compound of formula (I), or a pharmaceutically acceptable salt thereof, according to claim 1, the process comprising the condensation of an aldehyde of formula (II)



10 wherein the groups X¹ to X⁴, R¹ and R² are as defined in claim 1, with a compound of formula (a'), (b'), (c'), (d') or (e'), respectively:



- 35 -



- 10 wherein R³ and n are as defined in claim 1, and if desired, converting a compound of formula (I) into another compound of formula (I), and/or, if desired, converting a compound of formula (I) into a pharmaceutically acceptable salt thereof, and/or, if desired, converting a salt into a free compound, and/or, if desired, separating a mixture of isomers of a compound of formula (I) into the single isomers.
- 15
- 20
- 25
5. A pharmaceutical composition containing a suitable carrier and/or diluent and, as an active principle, a compound of formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof.
6. A compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt thereof, for use as a tyrosine kinase inhibitor.
7. Use of a compound of formula (I) as defined in claim 1, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for use as a tyrosine kinase inhibitor.

- 36 -

8. A compound of formula (I), according to claim 1, or a pharmaceutically acceptable salt thereof, for use as antiproliferative agent.

5 9. Use of a compound of formula (I), according to claim 1, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for use as antiproliferative agent.

10 10. A compound of formula (I), according to claim 1, or a pharmaceutically acceptable salt thereof, for use as anti-cancer agent or in the treatment of coronary artery disease or in the control of angiogenesis.

15 11. Use of a compound of formula (I), according to claim 1, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for use as anti-cancer agent, or in the treatment of coronary artery disease or in the control of angiogenesis.

20 12. Products containing a compound of formula (I), according to claim 1, or a pharmaceutically acceptable salt thereof, and an anti-tumour agent as a combined preparation for simultaneous, separate or sequential use in anti-cancer therapy.

INTERNATIONAL SEARCH REPORT

Int'l Application No.
PCT/EP 93/03536

A. CLASSIFICATION OF SUBJECT MATTER
IPC 5 C07D471/04 A61K31/435 // (C07D471/04, 221:00, 209:00)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 5 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO,A,91 13055 (ERBA) 5 September 1991 see page 14, line 7 - page 14, line 11; claims 1,7 -----	1,6,8,12

Further documents are listed in the continuation of box C.

Patent family members are listed in Annex.

* Special categories of cited documents :

- 'A' document defining the general state of the art which is not considered to be of particular relevance
- 'B' earlier document but published on or after the international filing date
- 'L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- 'O' document referring to an oral disclosure, use, exhibition or other means
- 'P' document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

13 April 1994

Date of mailing of the international search report

26.04.94

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Alfaro Faus, I

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No.
PCT/EP 93/03536

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO-A-9113055	05-09-91	AU-A-	7241291	18-09-91
		EP-A-	0470221	12-02-92
		JP-T-	4506081	22-10-92
		NZ-A-	237182	23-12-93